Quick Answer
ATOSSA THERAPEUTICS, INC. reported Total Revenue of $1.8 thousand for fiscal year 2015.
ATOSSA THERAPEUTICS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | -$34.77M -36.3% |
-$25.50M +15.3% |
-$30.09M -11.6% |
-$26.96M -30.8% |
-$20.61M -15.6% |
-$17.83M -3.4% |
| Diluted EPS | -$4.04 -32.9% |
-$3.04 -1166.7% |
-$0.24 -14.3% |
-$0.21 | — | — |
| Total Assets | $47.61M -37.7% |
$76.44M -20.6% |
$96.25M -22.1% |
$123.53M -12.6% |
$141.26M +229.8% |
$42.84M +195.6% |
| Cash and Equivalents | $41.30M -41.9% |
$71.08M -19.6% |
$88.46M -20.2% |
$110.89M -18.7% |
$136.38M +244.8% |
$39.55M +214.4% |
| Stockholders Equity | $39.35M -44.9% |
$71.48M -21.5% |
$91.02M -22.8% |
$117.96M -14.6% |
$138.14M +408.5% |
$27.17M +106.5% |
| R&D Expense | $21.18M +50.1% |
$14.12M -18.6% |
$17.33M +14.9% |
$15.08M +63.8% |
$9.21M +39.4% |
$6.61M -0.6% |
| Operating Income | -$37.14M -34.5% |
-$27.62M +12.0% |
-$31.38M -13.3% |
-$27.69M -34.9% |
-$20.52M -40.5% |
-$14.61M +15.4% |
| Gross Profit | — | — | — | — | — | — |
| Shares Outstanding | 8.61M +0.0% |
8.61M -93.1% |
125.30M -1.0% |
126.62M +0.0% |
126.62M +166.3% |
47.55M +420.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2016 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$8.69M | -20.2% | -3.2% |
| Diluted EPS | September 30, 2025 | -$0.07 | -16.7% | +0.0% |
| Total Assets | September 30, 2025 | $58.01M | -27.0% | -10.1% |
| Cash and Equivalents | September 30, 2025 | $51.84M | -30.7% | -10.4% |
| Stockholders Equity | September 30, 2025 | $49.79M | -32.4% | -13.7% |
| R&D Expense | September 30, 2025 | $5.37M | +57.4% | -2.4% |
| Operating Income | September 30, 2025 | -$9.25M | -44.9% | -2.3% |
| Gross Profit | June 30, 2016 | $0.00 | — | — |
| Shares Outstanding | September 30, 2025 | 129.17M | +3.1% | +0.0% |
- ATOSSA THERAPEUTICS, INC. reported Total Revenue of $1.8 thousand for fiscal year 2015.
- ATOSSA THERAPEUTICS, INC. showed a decrease of -95.6% in Total Revenue compared to the prior fiscal year.
- ATOSSA THERAPEUTICS, INC. reported Net Income of -$34.77 million for fiscal year 2025.
- ATOSSA THERAPEUTICS, INC. showed a decrease of -36.3% in Net Income compared to the prior fiscal year.
- ATOSSA THERAPEUTICS, INC. reported Diluted EPS of $4.04 per share (loss) for fiscal year 2025.
- ATOSSA THERAPEUTICS, INC. showed a decrease of -32.9% in Diluted EPS compared to the prior fiscal year.
- ATOSSA THERAPEUTICS, INC. reported Total Assets of $47.61 million for fiscal year 2025.
- ATOSSA THERAPEUTICS, INC. showed a decrease of -37.7% in Total Assets compared to the prior fiscal year.
- ATOSSA THERAPEUTICS, INC. reported Cash and Equivalents of $41.30 million for fiscal year 2025.
- ATOSSA THERAPEUTICS, INC. showed a decrease of -41.9% in Cash and Equivalents compared to the prior fiscal year.
- ATOSSA THERAPEUTICS, INC. reported Stockholders Equity of $39.35 million for fiscal year 2025.
- ATOSSA THERAPEUTICS, INC. showed a decrease of -44.9% in Stockholders Equity compared to the prior fiscal year.
- ATOSSA THERAPEUTICS, INC. reported R&D Expense of $21.18 million for fiscal year 2025.
- ATOSSA THERAPEUTICS, INC. showed an increase of +50.1% in R&D Expense compared to the prior fiscal year.
- ATOSSA THERAPEUTICS, INC. reported Operating Income of -$37.14 million for fiscal year 2025.
- ATOSSA THERAPEUTICS, INC. showed a decrease of -34.5% in Operating Income compared to the prior fiscal year.
- ATOSSA THERAPEUTICS, INC. reported Gross Profit of -$130.7 thousand for fiscal year 2015.
- ATOSSA THERAPEUTICS, INC. showed a decrease of -425.5% in Gross Profit compared to the prior fiscal year.
- ATOSSA THERAPEUTICS, INC. reported Shares Outstanding of 8.61 million shares for fiscal year 2025.
- ATOSSA THERAPEUTICS, INC. showed an increase of +0.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: